BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodríguez AJ, Abrahamsen B. Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. JBMR Plus 2021;5:e10522. [PMID: 34258509 DOI: 10.1002/jbm4.10522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Geusens P, Appelman-dijkstra N, Lems W, van den Bergh J. Romosozumab for the treatment of postmenopausal women at high risk of fracture. Expert Opinion on Biological Therapy 2022. [DOI: 10.1080/14712598.2022.2152320] [Reference Citation Analysis]
2 Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodriguez AJ. Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis. Bone 2022. [DOI: 10.1016/j.bone.2022.116610] [Reference Citation Analysis]
3 Lim EJ, Lee S, Kim JK, Kim H, Shin YH. The risk factors for subsequent fractures after distal radius fracture. J Bone Miner Metab 2022. [PMID: 35941252 DOI: 10.1007/s00774-022-01355-1] [Reference Citation Analysis]
4 Rodríguez AJ, Abrahamsen B. Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. JBMR Plus. [DOI: 10.1002/jbm4.10628] [Reference Citation Analysis]